Trial of tamoxifen at a dose of 40 mg daily after disease progression during tamoxifen therapy at a dose of 20 mg daily.

Suppr

超能文献

作者信息

Stewart J F, Minton M J, Rubens R D

出版信息

Cancer Treat Rep. 1982 Jun;66(6):1445-6.

PMID:7044536

Abstract

摘要

相似文献

Trial of tamoxifen at a dose of 40 mg daily after disease progression during tamoxifen therapy at a dose of 20 mg daily.

Cancer Treat Rep. 1982 Jun;66(6):1445-6.

Clinical pharmacology of tamoxifen in patients with breast cancer: comparison of traditional and loading dose schedules.他莫昔芬在乳腺癌患者中的临床药理学：传统给药方案与负荷剂量方案的比较

Cancer Treat Rep. 1980 Jun-Jul;64(6-7):765-73.

[Results of phase II clinical trial of Tamoxifen and Toremifen in two different doses in advanced breast cancer in postmenopausal women].[他莫昔芬和托瑞米芬两种不同剂量用于绝经后妇女晚期乳腺癌的II期临床试验结果]

Vopr Onkol. 1997;43(6):587-95.

Phase I/II trial of all-trans retinoic acid and tamoxifen in patients with advanced breast cancer.全反式维甲酸与他莫昔芬用于晚期乳腺癌患者的I/II期试验。

Clin Cancer Res. 1998 Mar;4(3):635-42.

Efficacy of tamoxifen as treatment of breast cancer.

Semin Oncol. 1997 Feb;24(1 Suppl 1):S1-48-S1-54.

[A randomized, double-blind, placebo-controlled, phase 3 trial comparing SMS 201-995 pa LAR plus tamoxifen versus tamoxifen plus placebo in women with locally recurrent or metastatic breast cancer].一项随机、双盲、安慰剂对照的3期试验，比较SMS 201-995 pa LAR联合他莫昔芬与他莫昔芬联合安慰剂治疗局部复发或转移性乳腺癌女性的疗效

Zentralbl Gynakol. 2001 Oct;123(10):557-61. doi: 10.1055/s-2001-19088.

Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial.阿那曲唑与他莫昔芬作为绝经后激素受体阳性乳腺癌女性术前治疗的比较：术前“瑞宁得”与他莫昔芬对比（PROACT）试验

Cancer. 2006 May 15;106(10):2095-103. doi: 10.1002/cncr.21872.

Clinical inquiries. Does tamoxifen prevent breast cancer?临床问题。他莫昔芬能预防乳腺癌吗？

J Fam Pract. 2001 Dec;50(12):1023.

Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial.与单纯使用他莫昔芬相比，表柔比星联合他莫昔芬每周给药作为可手术、淋巴结阳性老年乳腺癌患者辅助治疗的无病生存优势：法国辅助治疗研究组08试验的6年随访结果

J Clin Oncol. 2004 Dec 1;22(23):4622-30. doi: 10.1200/JCO.2004.02.145. Epub 2004 Oct 25.

Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen.对于完成5年他莫昔芬治疗的早期乳腺癌女性患者，来曲唑的晚期延长辅助治疗可改善其预后。

J Clin Oncol. 2008 Apr 20;26(12):1948-55. doi: 10.1200/JCO.2007.11.6798. Epub 2008 Mar 10.

引用本文的文献

Tamoxifen as adjuvant therapy in breast cancer. Current status.他莫昔芬作为乳腺癌辅助治疗的现状

Drugs. 1993 Nov;46(5):819-33. doi: 10.2165/00003495-199346050-00003.

A comparison of two doses of tamoxifen (Nolvadex) in postmenopausal women with advanced breast cancer: 10 mg bd versus 20 mg bd.两种剂量他莫昔芬（诺瓦得士）治疗绝经后晚期乳腺癌女性的比较：每日两次，每次10毫克与每日两次，每次20毫克。

Br J Cancer. 1984 Aug;50(2):199-205. doi: 10.1038/bjc.1984.163.

The value of high dose tamoxifen in postmenopausal breast cancer patients progressing on standard doses: a pilot study.高剂量他莫昔芬对标准剂量治疗后病情进展的绝经后乳腺癌患者的价值：一项初步研究。

Br J Cancer. 1988 Mar;57(3):320-1. doi: 10.1038/bjc.1988.72.

On the role of additive hormone monotherapy with tamoxifen, medroxyprogesterone acetate and aminoglutethimide, in advanced breast cancer.关于他莫昔芬、醋酸甲羟孕酮和氨鲁米特联合激素单一疗法在晚期乳腺癌中的作用

Klin Wochenschr. 1987 Oct 15;65(20):959-66. doi: 10.1007/BF01717830.

Tamoxifen metabolism: pharmacokinetic and in vitro study.他莫昔芬代谢：药代动力学及体外研究

Br J Cancer. 1989 Jul;60(1):30-5. doi: 10.1038/bjc.1989.214.

Endocrine therapy of metastatic breast cancer.转移性乳腺癌的内分泌治疗

J Endocrinol Invest. 1989 May;12(5):357-72. doi: 10.1007/BF03350007.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验